Literature DB >> 3023998

Thalidomide neuropathy: an electrophysiologic study.

A Lagueny, A Rommel, B Vignolly, A Taieb, M Vendeaud-Busquet, M S Doutre, J Julien.   

Abstract

Thalidomide is effective in the treatment of such disabling dermatologic diseases as aphthosis, discoid lupus erythematosus, and prurigo nodularis, in which other drugs fail. However, its use can induce neuropathy necessitating caution in its administration. It was found in this electrophysiologic study of 13 patients that the data best revealing neuropathy, even when clinical abnormalities were not apparent, were reduction of sensory nerve action potential amplitude on the sural nerve, increase of somatosensory evoked potential latency following sural nerve stimulation, and reduction of sensory action potential amplitude on stimulating the median nerve at the wrist. In two patients, electrophysiologic abnormalities had increased after withdrawal, suggesting a prolonged action of thalidomide. Timely reduction of dosage, after detection of changes indicating the onset of side effects, could reduce the risk of the sometimes rapid emergence of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023998     DOI: 10.1002/mus.880090907

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

Review 1.  Advances in understanding drug-induced neuropathies.

Authors:  Amanda C Peltier; James W Russell
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

3.  Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day.

Authors:  Maria Stella de Mello Ayres Putinatti; Joel Carlos Lastória; Carlos Roberto Padovani
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

Review 4.  Peripheral neuropathy and cancer.

Authors:  Arthur D Forman
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 5.  Medication-induced peripheral neuropathy.

Authors:  Louis H Weimer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

Review 6.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

7.  Peripheral Nerve Dysfunction in Middle-Aged Subjects Born with Thalidomide Embryopathy.

Authors:  Alessia Nicotra; Claus Newman; Martin Johnson; Oleg Eremin; Tim Friede; Omar Malik; Richard Nicholas
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

8.  Death and Rebirth of the Thalidomide Molecule: A Case of Thalidomide-Induced Sensory Neuropathy.

Authors:  Hassan Kesserwani
Journal:  Cureus       Date:  2021-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.